Chiba University, Chiba, Japan
Copyright 2016, American College of Chest Physicians. All Rights Reserved.
SESSION TITLE: Critical Care: ARDS/ALI
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: Pulmonary fibrosis is the final pathway of acute respiratory distress syndrome (ARDS). Recently, endothelial-to-mesenchymal transition (EndMT) had been shown to play an important role in pulmonary fibrosis. On the other hand, dipeptidyl peptidase (DPP)-4 was reported to play roles in EndMT in kidney. However its effects on EndMT and fibrosis initiation during lipopolysaccharide (LPS)-induced lung injury remain unknown. The aim of this study was to investigate the anti-EndMT effects of the DPP-4 inhibitor, vildagliptin in septic lung injury.
METHODS: The acute lung injury model was established by intraperitoneal injection of LPS in mice (5mg/kg for 3 consecutive days). The mice were treated with vehicle or vildagliptin (10mg/kg, once daily for 10 consecutive days) intraperitoneally. Lung samples from mice were investigated for cell dynamics and EndMT function using flow cytometry, immunohistochemical staining and quantitative polymerase chain reaction (qPCR) analysis.
RESULTS: Lung tissue revealed obvious inflammatory reactions 2 days after LPS challenge, and typical interstitial fibrosis 28 days after LPS challenge. Quantitative flow cytometric analysis revealed that the number of pulmonary vascular endothelial cells (PVECs) expressing alpha-smooth muscle actin (α-SMA) or fibroblast-specific protein 1 (FSP1) was increased since 2 days after LPS challenge, which was also confirmed by qPCR of isolated PVECs. All of these changes were alleviated by intraperitoneal injection of vildagliptin.
CONCLUSIONS: Inhibiting DPP-4 signaling could ameliorate pulmonary fibrosis via downregulation of EndMT in LPS-induced lung injury.
CLINICAL IMPLICATIONS: Inhibiting DPP-4 may be a therapeutic target for treating post-ARDS pulmonary fibrosis.
DISCLOSURE: The following authors have nothing to disclose: Toshio Suzuki, James West, Rintaro Nishimura, Takeshi Kawasaki, Ayumi Sekine, Takashi Urushibara, Yuji Tada, Koichiro Tatsumi
No Product/Research Disclosure Information
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.